Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
sEphB4-HSA in BCG-Unresponsive Bladder Cancer
NCT03552796Phase 1Withdrawn
- Sponsor
- University of Southern California
- Start
- Aug 2023
- Primary completion
- Aug 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sephb4-hsa in bladder carcinoma, sponsored by University of Southern California. Primary endpoints: Incidence of adverse events up to 6 months and Maximum tolerated dose (MTD) and recommended phase II dose (RP2D) up to 6 months. Planned start Aug 2023; status: withdrawn.
02
Drugs
sephb4-hsa
03
Conditions
bladder carcinoma
Beyond the preview
Go deeper on NCT03552796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03552796.